UK NCRI cites RADICALS-RT as one of their top three achievements of the year Thursday, February 04, 2021 The UK National Cancer Research Institute (NCRI) has cited the CCTG PR13 study (RADICALS-RT) as one of their top three achievements of the year in their 2019-2020 annual report! https://www.ncri.org.uk/wp-content/uploads/NCRI-Prostate-Group-Annual-Report-2019-20.pdf The RADICALS: Radiotherapy and Androgen Deprivation In Combination After Local Surgery study, looked at the optimal timing of radiotherapy after radical prostatectomy for prostate cancer. The aim was to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prostate-specific antigen (PSA) biochemical progression. Findings (Lancet Oncology) Between Nov 22, 2007, and Dec 30, 2016, 1396 patients were randomly assigned, 699 (50%) to salvage radiotherapy and 697 (50%) to adjuvant radiotherapy. Allocated groups were balanced with a median age of 65 years (IQR 60–68). Median follow-up was 4·9 years (IQR 3·0–6·1). 649 (93%) of 697 participants in the adjuvant radiotherapy group reported radiotherapy within 6 months; 228 (33%) of 699 in the salvage radiotherapy group reported radiotherapy within 8 years after randomisation. With 169 events, 5-year biochemical progression-free survival was 85% for those in the adjuvant radiotherapy group and 88% for those in the salvage radiotherapy group (HR 1·10, 95% CI 0·81–1·49; p=0·56). Freedom from non-protocol hormone therapy at 5 years was 93% for those in the adjuvant radiotherapy group versus 92% for those in the salvage radiotherapy group (HR 0·88, 95% CI 0·58–1·33; p=0·53). Self-reported urinary incontinence was worse at 1 year for those in the adjuvant radiotherapy group (mean score 4·8 vs 4·0; p=0·0023). Grade 3–4 urethral stricture within 2 years was reported in 6% of individuals in the adjuvant radiotherapy group versus 4% in the salvage radiotherapy group (p=0·020). Find out more on the CCTG PR13 study page.
